Stored platelet hemostatic phenotype and function is not altered when donors are on testosterone replacement therapy
Transfusion · 2024
DOI: 10.1111/trf.17926 ↗Kurz gefasst
Fachartikel in der Zeitschrift Transfusion, 2024. Verfasst von Alisha Chitrakar und 3 weiteren Autor:innen. Beteiligte Einrichtung: Vitalant Research Institute, Denver, Colorado, USA. Hauptthemen laut MEDLINE: Testosterone, Blood Platelets, Hormone Replacement Therapy, Blood Preservation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, National Heart, Lung, and Blood Institute.
Abstract (Originalsprache)
Background
Critical shortages in the national blood supply have led to a re‐evaluation of previously overlooked donor sources for blood products. As a part of that effort, red blood cells collected from therapeutic phlebotomy of donors on testosterone replacement therapy (TRT) have been conditionally approved for transfusion. However, platelets from TRT donors are not currently approved for use due to limited data on effects of supraphysiologic testosterone on recipient safety and platelet function. The objective of this study was to provide a comprehensive profile of phenotype and function in platelets from TRT and control donors. Study Design and Methods Platelets in plasma were collected from TRT and control donors ( N = 10 per group; age‐ and sex‐matched) and stored at room temperature for 7 days. On storage Day 1 (D1) and Day 7 (D7), platelet products were analyzed for platelet count, metabolic parameters (i.e., glucose, lactate, mitochondrial function), surface receptor expression, aggregation, thrombin generation, and thrombus formation under physiological flow conditions.
Results
TRT donor platelets were not significantly different than control donor platelets in terms of count, surface phenotype, metabolic function, ability to aggregate, thrombin generation, or ability to form occlusive thrombus under arterial flow regimes. Both groups were similar to each other by D7, but had significantly lost hemostatic function compared to D1.
Discussion
Platelets derived from donors undergoing TRT have similar phenotypic and functional profiles compared to those derived from control donors. This suggests that therapeutic phlebotomy of TRT donors may provide a useful source for platelet products.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vitalant Research Institute, Denver, Colorado, USA.
- Department of Pathology, University of Colorado Denver Anschutz Medical Campus, Aurora, Colorado, USA.
ORCID-Profile: Tamir Kanias, Kimberly A Thomas
Förderung
- NHLBI NIH HHS
- National Heart, Lung, and Blood Institute
Zitieren
APA
Chitrakar, A., Bean, S. M., Kanias, T., & Thomas, K. A. (2024). Stored platelet hemostatic phenotype and function is not altered when donors are on testosterone replacement therapy. Transfusion. https://doi.org/10.1111/trf.17926
Vancouver
Chitrakar A, Bean SM, Kanias T, Thomas KA. Stored platelet hemostatic phenotype and function is not altered when donors are on testosterone replacement therapy. Transfusion. 2024. doi:10.1111/trf.17926
BibTeX
@article{Chitrakar2024,
author = {Chitrakar, Alisha and Bean, Scott-Wesley M and Kanias, Tamir and Thomas, Kimberly A},
title = {Stored platelet hemostatic phenotype and function is not altered when donors are on testosterone replacement therapy},
journal = {Transfusion},
year = {2024},
doi = {10.1111/trf.17926}
}
EUVIMED